Aquestive Therapeutics, Inc. Stock-Based Compensation
Aquestive Therapeutics, Inc. (AQST) reported Stock-Based Compensation of $5.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- Aquestive Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.90M, a 53.66% increase year-over-year.
- Aquestive Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.32M, a 46.06% increase year-over-year.
- Aquestive Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.38M, a 42.74% decline year-over-year.
- Aquestive Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.78M, a 76.09% increase year-over-year.
- Aquestive Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $7.62M, a 7.40% increase from fiscal 2024.
- Aquestive Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $7.10M, a 164.00% increase from fiscal 2023.
- Aquestive Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $2.69M, a 38.62% decline from fiscal 2022.
- Aquestive Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $4.38M, a 35.75% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $5.21M 10-Q · filed 2026-08-11 | $6.59M derived: sum of 3 quarters · filed 2026-08-11 | $9.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.32M 10-Q · filed 2026-05-13 | $3.69M derived: sum of 2 quarters · filed 2026-05-13 | $6.47M derived: sum of 3 quarters · filed 2026-05-13 | $8.36M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $4.15M derived: sum of 2 quarters · filed 2026-03-04 | $6.04M derived: sum of 3 quarters · filed 2026-08-11 | $7.62M 10-K · filed 2026-03-04 |
| 2025-09-30 | $2.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.66M derived: sum of 2 quarters · filed 2026-08-11 | $6.25M 10-Q · filed 2025-11-05 | $8.65M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.47M 10-Q · filed 2026-08-11 | $5.87M derived: sum of 3 quarters · filed 2026-08-11 | $7.45M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.59M 10-Q · filed 2026-05-13 | $3.99M derived: sum of 2 quarters · filed 2026-05-13 | $5.57M derived: sum of 3 quarters · filed 2026-05-13 | $7.11M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $3.98M derived: sum of 2 quarters · filed 2026-03-04 | $5.52M derived: sum of 3 quarters · filed 2026-03-04 | $7.10M 10-K · filed 2026-03-04 |
| 2024-09-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.12M derived: sum of 2 quarters · filed 2025-11-05 | $4.70M 10-Q · filed 2025-11-05 | $5.64M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $3.12M 10-Q · filed 2025-08-11 | $4.06M derived: sum of 3 quarters · filed 2025-08-11 | $4.83M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $1.58M 10-Q · filed 2025-05-12 | $2.52M derived: sum of 2 quarters · filed 2025-05-12 | $3.29M derived: sum of 3 quarters · filed 2025-05-12 | $3.92M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $940.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $1.71M derived: sum of 2 quarters · filed 2025-03-05 | $2.35M derived: sum of 3 quarters · filed 2025-03-05 | $2.69M 10-K · filed 2025-03-05 |
| 2023-09-30 | $774.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $1.41M derived: sum of 2 quarters · filed 2024-11-04 | $1.75M 10-Q · filed 2024-11-04 | $2.46M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $631.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $975.00K 10-Q · filed 2024-08-06 | $1.69M derived: sum of 3 quarters · filed 2024-08-06 | $2.22M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $344.00K 10-Q · filed 2024-05-07 | $1.06M derived: sum of 2 quarters · filed 2024-05-07 | $1.59M derived: sum of 3 quarters · filed 2024-05-07 | $3.81M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $714.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $1.25M derived: sum of 2 quarters · filed 2024-03-05 | $3.47M derived: sum of 3 quarters · filed 2024-03-05 | $4.38M 10-K · filed 2024-03-05 |
| 2022-09-30 | $535.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $2.75M derived: sum of 2 quarters · filed 2023-11-06 | $3.67M 10-Q · filed 2023-11-06 | $5.36M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $2.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $3.13M 10-Q · filed 2023-08-07 | $4.82M derived: sum of 3 quarters · filed 2023-08-07 | $6.72M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $913.00K 10-Q · filed 2023-05-02 | $2.60M derived: sum of 2 quarters · filed 2023-05-02 | $4.50M derived: sum of 3 quarters · filed 2023-05-02 | $6.22M derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $3.59M derived: sum of 2 quarters · filed 2023-03-31 | $5.31M derived: sum of 3 quarters · filed 2023-03-31 | $6.82M 10-K · filed 2023-03-31 |
| 2021-09-30 | $1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $3.62M derived: sum of 2 quarters · filed 2022-11-01 | $5.13M 10-Q · filed 2022-11-01 | $6.66M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $1.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $3.23M 10-Q · filed 2022-08-02 | $4.76M derived: sum of 3 quarters · filed 2022-08-02 | $6.18M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $1.51M 10-Q · filed 2022-05-04 | $3.04M derived: sum of 2 quarters · filed 2022-05-04 | $4.46M derived: sum of 3 quarters · filed 2022-05-04 | $6.23M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $2.96M derived: sum of 2 quarters · filed 2022-03-08 | $4.72M derived: sum of 3 quarters · filed 2022-03-08 | $6.58M 10-K · filed 2022-03-08 |
| 2020-09-30 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $3.19M derived: sum of 2 quarters · filed 2021-11-02 | $5.05M 10-Q · filed 2021-11-02 | $6.92M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $3.63M 10-Q · filed 2021-08-03 | $5.50M derived: sum of 3 quarters · filed 2021-08-03 | $7.37M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $1.86M 10-Q · filed 2021-05-04 | $3.73M derived: sum of 2 quarters · filed 2021-05-04 | $5.60M derived: sum of 3 quarters · filed 2021-05-04 | $7.41M derived: sum of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $3.74M derived: sum of 2 quarters · filed 2021-03-09 | $5.55M derived: sum of 3 quarters · filed 2021-03-09 | $7.07M 10-K · filed 2021-03-09 |
| 2019-09-30 | $1.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $3.68M derived: sum of 2 quarters · filed 2020-11-04 | $5.20M 10-Q · filed 2020-11-04 | $6.60M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $3.33M 10-Q · filed 2020-08-04 | $4.73M derived: sum of 3 quarters · filed 2020-08-04 | $5.96M derived: sum of 4 quarters · filed 2020-08-04 |
| 2019-03-31 | $1.52M 10-Q · filed 2020-05-05 | $2.92M derived: sum of 2 quarters · filed 2020-05-05 | $4.16M derived: sum of 3 quarters · filed 2020-05-05 | $31.46M derived: sum of 4 quarters · filed 2020-05-05 |
| 2018-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $2.63M derived: sum of 2 quarters · filed 2020-03-11 | $29.94M derived: sum of 3 quarters · filed 2020-03-11 | $29.94M 10-K · filed 2020-03-11 |
| 2018-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $28.54M derived: sum of 2 quarters · filed 2019-11-05 | $28.54M 10-Q · filed 2019-11-05 | $28.54M derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | $27.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $27.30M 10-Q · filed 2019-08-06 | $27.30M derived: sum of 3 quarters · filed 2019-08-06 | $27.30M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-08 | $0.00 derived: sum of 2 quarters · filed 2019-05-08 | $0.00 derived: sum of 3 quarters · filed 2019-05-08 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $0.00 derived: sum of 2 quarters · filed 2019-03-14 | $0.00 10-K · filed 2019-03-14 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |